Clinical Chemistry Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 46: 416-418, 2000;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dumon, J.-C.
Right arrow Articles by Body, J.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dumon, J.-C.
Right arrow Articles by Body, J.-J.
Related Collections
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2000;46:416-418.)
© 2000 American Association for Clinical Chemistry, Inc.

Technical Briefs

Technical and Clinical Validation of an Immunoradiometric Assay for Circulating Parathyroid Hormone-related Protein

Jean-Claude Dumon1, Todd Jensen2, Bruce Lueddecke2, Jon Spring2, Josette Barlé1 and Jean-Jacques Body1,a

1 Laboratory of Endocrinology/Bone Metabolism, Laboratory of Clinical Chemistry and Supportive Care Clinic, Service de Médecine et Laboratoire d’Investigation Clinique H.J. Tagnon, Institut Jules Bordet, Université Libre de Bruxelles, 1000 Brussels, Belgium;
2 DiaSorin Corp., Stillwater, MN 55082;
a address correspondence to this author at: Institut Jules Bordet, Rue Héger-Bordet 1, 1000 Brussels, Belgium

Parathyroid hormone-related protein (PTHrP) plays a key role in hypercalcemia of malignancy (HM), particularly in humoral HM (HHM) (1)(2). Serum PTHrP is increased in 47–100% of HM patients (3)(4)(5)(6) and in almost all patients with HHM. In up to two-thirds of hypercalcemic patients with bone metastases, serum PTHrP is increased (5)(7). PTHrP assays may aid in the diagnosis of HHM (8).

IRMAs that measure large N-terminal regions appear to be optimal for HM evaluation (9). With the first commercially available IRMA (Nichols Institute), PTHrP concentrations were found to be increased in 40 of 81 (49%) HM patients. Moreover, healthy subjects had detectable values up to 2.6 pmol/L (10), contrary to some reports (5)(8)(11). With an IRMA from Mitsubishi Petrochemical Co (12), PTHrP was increased in all 46 studied patients with hypercalcemia and solid tumors, and most healthy subjects had values <1 pmol/L. However, almost all patients had HHM, and the specificity toward normocalcemic cancer (C.NoCa) patients was not thoroughly investigated.

We have evaluated a commercially available PTHrP IRMA. We particularly studied the assay specificity for HM patients compared with normocalcemic patients presenting an active cancer, with patients in complete remission from their cancer, and with patients suffering from osteopenia, osteoporosis, or chronic renal failure (CRF).

The first control group included 94 patients (88 women and 6 men), median age 61 years (range, 26–80 years), referred to our bone clinic for a low bone mass or established osteoporosis. The patients were classified (13) as follows: 39 osteopenic (T score at the lumbar spine of -1.78 ± 0.09, mean ± SE); 29 osteoporotic (T score -3.16 ± 0.10); 26 established . . . [Full Text of this Article]


Acknowledgments


Footnotes


References






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Association for Clinical Chemistry.